Literature DB >> 7691441

Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin.

J Leinonen1, T Lövgren, T Vornanen, U H Stenman.   

Abstract

We have developed a procedure for simultaneous immunofluorometric assay (IFMA) of prostate-specific antigen (PSA) and its complex with alpha 1-antichymotrypsin (ACT). A PSA-specific monoclonal antibody, which captures both free PSA and the PSA-ACT complex, was used as solid-phase antibody. Total PSA immunoreactivity was measured with a Eu(3+)-labeled PSA antibody that reacted with both free PSA and PSA-ACT. PSA-ACT was assayed simultaneously with a Sm(3+)-labeled polyclonal ACT antibody as a tracer. As standard we used pooled serum in which most of the PSA occurred as the PSA-ACT complex. The assay range was 0.03-500 micrograms/L for total PSA and 0.16-450 micrograms/L for PSA-ACT. In comparison with the assay for total PSA, assay of the PSA-ACT/PSA ratio improved the clinical specificity for cancer by reducing the number of false-positive results in prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691441

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

Review 1.  Complexed prostate-specific antigen improvement in detecting prostate cancer.

Authors:  K Okihara; R J Babaian
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 3.092

2.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

Review 3.  Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Authors:  David Ulmert; M Frank O'Brien; Anders S Bjartell; Hans Lilja
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

4.  Equivalent recognition of free and ACT-complexed PSA in a monoclonal-polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody.

Authors:  Z Zhou; E G Armstrong; A Belenky; J V Freeman; K K Yeung
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

5.  Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels.

Authors:  R M Hoffman; D L Clanon; B Littenberg; J J Frank; J C Peirce
Journal:  J Gen Intern Med       Date:  2000-10       Impact factor: 5.128

6.  Stability of total and free prostate specific antigen in serum samples at different storage conditions.

Authors:  G Rajani Kumari; T Malati
Journal:  Indian J Clin Biochem       Date:  2004-07

7.  Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building.

Authors:  B O Villoutreix; H Lilja; K Pettersson; T Lövgren; O Teleman
Journal:  Protein Sci       Date:  1996-05       Impact factor: 6.725

8.  Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases.

Authors:  G H Borchert; D N Melegos; G Tomlinson; M Giai; R Roagna; R Ponzone; L Sgro; E P Diamandis
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.

Authors:  O Nilsson; A Peter; I Andersson; K Nilsson; B Grundström; B Karlsson
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Differential overexpression of SERPINA3 in human prion diseases.

Authors:  S Vanni; F Moda; M Zattoni; E Bistaffa; E De Cecco; M Rossi; G Giaccone; F Tagliavini; S Haïk; J P Deslys; G Zanusso; J W Ironside; I Ferrer; G G Kovacs; G Legname
Journal:  Sci Rep       Date:  2017-11-15       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.